STMC-103H is under clinical development by Siolta Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STMC-103H’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STMC-103H is under development for the treatment and prevention of atopic immunoglobulin E-mediated allergic disorder, allergic asthma, food allergy, atopic dermatitis, allergic rhinitis and other allergic diseases. It is a live bacteria containing consortia of intestinal bacteria and is administered through oral route.
Siolta Therapeutics overview
Siolta Therapeutics, is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company is headquartered in United States.
For a complete picture of STMC-103H’s drug-specific PTSR and LoA scores, buy the report here.